Seto Katsutoshi, Kuroda Hiroaki, Yoshida Tatsuya, Sakata Shozo, Mizuno Tetsuya, Sakakura Noriaki, Hida Toyoaki, Yatabe Yasushi, Sakao Yukinori
Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan,
Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Cancer Manag Res. 2018 Jul 18;10:2117-2124. doi: 10.2147/CMAR.S147569. eCollection 2018.
There have been few studies that have fully elucidated the relationship between genomic mutations in pulmonary adenocarcinomas and occult lymph node (LN) metastases (pN1-2) despite a preoperative clinical N0 stage (cN0). It is well known that anaplastic lymphoma kinase () rearrangements are more likely to occur in younger patients with high grade tumors. The aim of this study was to investigate the genomic status, examine the clinicopathologic features, and evaluate whether mutations are associated with occult LN metastases.
We retrospectively evaluated 459 Japanese patients who underwent pulmonary resection of cN0 adenocarcinomas between January 2012 and December 2015. The clinicopathologic characteristics, including age, sex, smoking index, tumor maximum diameter and consolidation/tumor ratio on computed tomography (CT), maximum standardized uptake value on positron emission tomography (PET) and gene mutations (epidermal growth factor receptor [], , and kirsten ras genes (), were evaluated.
and and mutations were all mutually exclusive. Among 324 patients found to have mutations, was involved in 19 (5.9%), in 266 (82.1%), and in 39 (12.0%). The incidence of occult LN metastases did not differ significantly between those with or without mutations (=0.27). On univariate and multivariate analyses, tumors with were more likely to have occult LN metastases (=0.03). In cN0 tumors with , pN1 was diagnosed in 26.3% and pN2 in 10.5%, whereas pN1 or pN2 stage was found in <10.0% in those with or mutations or with no mutations at all. No significant difference was found in the 2-year disease-free survival among those with gene mutations (=0.08).
This study highlights the frequency of PET- and CT-negative occult LN metastases in resected adenocarcinomas with rearrangement. Our multivariate analysis showed that rearrangements were associated with a significantly higher incidence of occult LN metastasis compared with -negative adenocarcinomas.
尽管术前临床分期为N0期(cN0),但很少有研究能完全阐明肺腺癌基因组突变与隐匿性淋巴结(LN)转移(pN1 - 2)之间的关系。众所周知,间变性淋巴瘤激酶(ALK)重排在年轻的高级别肿瘤患者中更易发生。本研究的目的是调查基因组状态,检查临床病理特征,并评估ALK突变是否与隐匿性LN转移相关。
我们回顾性评估了2012年1月至2015年12月期间接受cN0腺癌肺切除术的459例日本患者。评估了临床病理特征,包括年龄、性别、吸烟指数、肿瘤最大直径以及计算机断层扫描(CT)上的实变/肿瘤比率、正电子发射断层扫描(PET)上的最大标准化摄取值和基因突变(表皮生长因子受体[EGFR]、ALK和 Kirsten 大鼠肉瘤病毒癌基因(KRAS))。
EGFR、ALK和KRAS突变均相互排斥。在324例发现有突变的患者中,ALK突变19例(5.9%),EGFR突变266例(82.1%),KRAS突变39例(12.0%)。有或无ALK突变患者的隐匿性LN转移发生率无显著差异(P = 0.27)。单因素和多因素分析显示,ALK阳性肿瘤更易发生隐匿性LN转移(P = 0.03)。在cN0的ALK阳性肿瘤中,pN1诊断率为26.3%,pN2为10.5%,而在ALK或KRAS突变或无突变的患者中,pN1或pN2分期的发现率<10.0%。基因突变患者的2年无病生存率无显著差异(P = 0.08)。
本研究突出了在ALK重排的切除腺癌中PET和CT阴性的隐匿性LN转移的频率。我们的多因素分析表明,与ALK阴性腺癌相比,ALK重排与隐匿性LN转移的发生率显著更高相关。